BCDA

BioCardia, Inc.

0.66 USD
+0.00 (+0.30%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BioCardia, Inc. stock is up 50.23% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.71% of the previous 27 December’s closed higher than November. 100% of analysts rate it a buy.

About BioCardia, Inc.

BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy.